Страна: Малайзія
мова: англійська
Джерело: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
CILOSTAZOL
A. MENARINI SINGAPORE PTE. LTD.
CILOSTAZOL
100 Tablets
KOREA OTSUKA PHARMACEUTICAL CO LTD
1 - ANTIPLATELET AGENT - PLETAAL Tablets 50 mg PLETAAL Tablets 100 mg < Cilostazol > Designated Drug and Prescription -only Drug Storage : Store below 30℃. Expiration date : Three years after the date of manufacture. (The expiration date is indicated on the package.) CONTRAINDICATIONS Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III -IV cong estive heart failure. Pletaal is contraindicated in patients with congestive heart failure of any severity. Pletaal is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial ble eding. P letaal inhibits platelet aggregation in a reversible manner. Pletaal is contraindicated in patients with known or suspected hypersensitivity to any of its components. DESCRIPTION 1. Composition Each tablet of PLETAAL Tablets 50 mg contains 50 mg of cilostazol and the following inactive ingredients: microcrystalline cellulose, corn starch, carboxymethyl cellulose calcium, hydroxypropyl methyl cellulose 2910, and magnesium stearate . Each tablet of PLETAAL Tablets 100 mg contains 100 mg of cilostaz ol and the following inactive ingredients: microcrystalline cellulose, corn starch, carboxymethyl cellulose calcium, hydroxypropyl methyl cellulose 2910, and magnesium stearate . 2. Product Description Pletaal Tablets are white compressed tablets. Appear ance Diame - ter (mm) Thick - ness (mm) Weight (mg) Code PLETAAL Tablets 50 mg 7 2.5 Approx. 115 OG31 PLETAAL Tablets 100 mg 8 3.0 Approx. 170 OG30 INDICATIONS Pletaal is indicated for the improvement of the maximal and pain -free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis. Pletaal is indicated for p revention of recurrence of cerebral infarction (excluding cardiogenic cerebral embolism) . The effects of PLE Прочитайте повний документ